FDA Panel Rejects MDMA for PTSD Treatment Over Data Concerns

Advisers cite flawed study design, potential bias, and safety risks in their recommendation against approval.

Overview

FDA advisory panel votes overwhelmingly against recommending MDMA for PTSD treatment, citing flawed data and significant risks.
Critics highlight issues such as potential bias in trial participants, lack of diversity, and allegations of misconduct.
Lykos Therapeutics, the company behind the trials, plans to address concerns and continue working with the FDA.
Advocates argue that MDMA-assisted therapy offers hope for PTSD patients who have not responded to traditional treatments.
The FDA's final decision, expected by August 11, could set a precedent for the approval of other psychedelic drugs.